?Diabetic foot osteomyelitis. Other osteomyelitis
Conditions
Interventions
Intervention 1: Tab. ciprofloxacin 500 mg, PO, BD, 6 weeks
Cap. clindamycin 300 mg, PO, TDS, 6 weeks. Intervention 2: Tab. ciprofloxacin 500 mg, PO, BD, 12 weeks
Cap. clindamycin 300 mg, PO, TDS, 12 w
Treatment - Drugs
Tab. ciprofloxacin 500 mg, PO, BD, 6 weeks
Cap. clindamycin 300 mg, PO, TDS, 6 weeks
Tab. ciprofloxacin 500 mg, PO, BD, 12 weeks
Cap. clindamycin 300 mg, PO, TDS, 12 weeks
Sponsors
Vice Chancellor for Research, Ardabil University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion main criteria: confirmed the diagnosis of osteomyelitis with no surgery in patients with diabetic foot; absence of chronic liver, renal, coronary arteries, anemia, rheumatism,...; absence of resistance against ciprofloxacin and clindamycin; no recent use of ciprofloxacin and clindamycin; absence of marked obesity (BMI more than 30) Exclusion main criteria: surgical intervention at any time of the study; any disorder factors during the study follow-up and treatment; absence of etiologic agents resistance against the used antibiotics; absence of posterior and anterior pulse (by arterial Doppler test); pregnancy and absence of drug gastrointestinal complications; existence of drug complication against ciprofloxacin and clindamycin during the study; resistance against ciprofloxacin and clindamycin.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Radiography. Timepoint: At the begining and end of the study. Method of measurement: Inflammation and air in the soft tissue, cortical bone destruction, irregular margins of skin at the wound site and in chronic cases of cortical erosions-reaction Periosteal, sclerosis and squestra.;Hb A1c. Timepoint: At the begining and end of the study. Method of measurement: %, chromatography.;ESR. Timepoint: At the begining and every two weeks until the end of the study. Method of measurement: mm/hr, ESR reader.;Positive probing test. Timepoint: At the begining of the study. Method of measurement: Touch or contact with prob.;FBS. Timepoint: at least 8 hrs fasting then at the begining and every two weeks until the end of the study. Method of measurement: mg/dl, autoanalyser.;2h pp Glu. Timepoint: at 2 hrs after glucose administration at the begining and every two weeks until the end of the study. Method of measurement: mg/dl, autoanalyser.;Creatinine. Timepoint: at the begining and end of the study. Method of measurement: mg/dl, autoanalyser.;Albumin. Timepoint: at the begining and every two weeks until the end of the study. Method of measurement: g/dl, autoanalyser.;The surface and depth measure of the ulcer. Timepoint: at the begining and end of the study. Method of measurement: mm2.;Microbial culture and antibiogram. Timepoint: at the begining of the study. Method of measurement: S or R, culture in microbial media and biochemical test.;Blood cell count. Timepoint: at the begining and every two weeks until the end of the study. Method of measurement: *10 9 /L, hematology cell counter.;WBC diff count. Timepoint: at the begining and every two weeks until the end of the study. Method of measurement: *10 9 /L, hematology cell counter.;CRP. Timepoint: at the begining and every two weeks until the end of the study. Method of measurement: mg/dl, Nycocard.;RBC indices: MCV, MCH, MCHC. Timepoint: at the begining and every two weeks until the end of the study. Method of measurement: fl, | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElnaz Afrozeh
Ardabil Medical University
Outcome results
None listed